HORIZON: Open-label extension studies evaluating repeated intravitreal ranibizumab in neovascular AMD and macular oedema due to retinal vein occlusion

Source: Ophthalmology
Area: News
Two studies (HORIZON) published early online in Ophthalmology have reported outcomes of extended use ranibizumab for neovascular age-related macular degeneration, and macular oedema due to retinal vein occlusion, with mixed results on efficacy.   The HORIZON trial was designed to obtain additional information about the effects of ranibizumab in 2 patient cohorts:   . Cohort 1 included patients with neovascular age-related macular degeneration who had completed the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA), the Anti-VEGF Antibody (Read more...)

Full Story →